June 1, 2024 08:00 AM EDT
R&D

BMS de­tails con­fir­ma­to­ry tri­al win for KRAS in­hibitor Kraza­ti

Katherine Lewin

News Reporter

Bris­tol My­ers Squibb said its KRAS can­cer drug Kraza­ti met the pri­ma­ry end­point in a Phase 3 con­fir­ma­to­ry tri­al in pa­tients with non-small cell lung …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times